PDCD1 and cancer: In addition to monotherapy with anti-PD-1/PD-L1 antibodies, combination therapy with chemotherapy and molecular target therapy as well as combination therapy with anti-PD-1 and anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) antibodies is now widely used in cancer treatment with ICIs [2].